Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 11/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.44 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9931336 | 0.89 | CCR2 (0.65) | CCR2MAPTTDP1PKMGLO1 | |
| SCHEMBL9930635 | 0.80 | CCR2 (0.64) | CCR2PKM | |
| SCHEMBL9930395 | 0.79 | CCR2 (0.61) | CCR2PKM | |
| SCHEMBL24152420 | 0.77 | HTR2C (0.61) | MAPTTDP1PKMSMYD3 | |
| SCHEMBL9930527 | 0.71 | CCR2 (0.61) | CCR2PKM | |
| SCHEMBL4907229 | 0.71 | POLB (0.60) | MAPTTDP1PKMSMYD3 | |
| SCHEMBL5843373 | 0.71 | SMYD3 (0.53) | MAPTTDP1PKMGLO1SMYD3 | |
| SCHEMBL3249962 | 0.70 | PKM (0.54) | MAPTTDP1PKMGLO1SMYD3 | |
| SCHEMBL9931337 | 0.69 | CCR2 (0.72) | CCR2PKM | |
| SCHEMBL9930799 | 0.69 | CCR2 (0.72) | CCR2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9603834-B2 | 1,2- bis-sulfonamide derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20160228407-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. | 2016-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228407-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CXCR2, CCR2, CX3CR1 | CCR2 2/4885MAPT 4542/4885TDP1 4719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.